Applied Finance Capital Management LLC reduced its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 3.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 50,769 shares of the medical research company's stock after selling 1,744 shares during the period. Applied Finance Capital Management LLC's holdings in Thermo Fisher Scientific were worth $26,411,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds have also modified their holdings of the stock. Stonegate Investment Group LLC lifted its holdings in Thermo Fisher Scientific by 0.3% during the 4th quarter. Stonegate Investment Group LLC now owns 6,788 shares of the medical research company's stock valued at $3,531,000 after purchasing an additional 18 shares during the last quarter. Semus Wealth Partners LLC raised its stake in shares of Thermo Fisher Scientific by 4.0% in the fourth quarter. Semus Wealth Partners LLC now owns 471 shares of the medical research company's stock valued at $245,000 after acquiring an additional 18 shares during the last quarter. Bangor Savings Bank grew its position in Thermo Fisher Scientific by 6.0% during the 4th quarter. Bangor Savings Bank now owns 334 shares of the medical research company's stock worth $174,000 after acquiring an additional 19 shares during the last quarter. Eagle Rock Investment Company LLC increased its holdings in Thermo Fisher Scientific by 0.3% during the 4th quarter. Eagle Rock Investment Company LLC now owns 7,463 shares of the medical research company's stock valued at $3,882,000 after purchasing an additional 19 shares in the last quarter. Finally, KRS Capital Management LLC boosted its stake in Thermo Fisher Scientific by 1.5% in the fourth quarter. KRS Capital Management LLC now owns 1,317 shares of the medical research company's stock worth $685,000 after purchasing an additional 20 shares in the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of analysts have recently weighed in on TMO shares. Sanford C. Bernstein upgraded Thermo Fisher Scientific from a "market perform" rating to an "outperform" rating and set a $630.00 target price for the company in a research note on Friday, January 10th. UBS Group boosted their target price on shares of Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a "buy" rating in a research note on Friday, January 31st. Wells Fargo & Company increased their price target on shares of Thermo Fisher Scientific from $660.00 to $680.00 and gave the company an "overweight" rating in a research note on Friday, January 31st. StockNews.com upgraded shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Tuesday, January 14th. Finally, Scotiabank increased their price objective on Thermo Fisher Scientific from $605.00 to $650.00 and gave the company a "sector perform" rating in a research report on Monday, February 3rd. Four research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $647.43.
View Our Latest Stock Analysis on Thermo Fisher Scientific
Thermo Fisher Scientific Trading Up 2.4 %
TMO traded up $10.47 during mid-day trading on Friday, hitting $437.91. The stock had a trading volume of 2,656,544 shares, compared to its average volume of 1,698,824. The firm has a market capitalization of $165.21 billion, a price-to-earnings ratio of 26.49, a price-to-earnings-growth ratio of 2.99 and a beta of 0.86. Thermo Fisher Scientific Inc. has a 1-year low of $409.85 and a 1-year high of $627.88. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. The stock's fifty day simple moving average is $510.56 and its 200-day simple moving average is $538.78.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. As a group, research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.
Thermo Fisher Scientific Increases Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th will be given a dividend of $0.43 per share. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.39. The ex-dividend date is Friday, March 14th. This represents a $1.72 annualized dividend and a dividend yield of 0.39%. Thermo Fisher Scientific's dividend payout ratio is currently 10.41%.
Insider Buying and Selling
In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $175,677.00. Following the sale, the executive vice president now owns 16,363 shares in the company, valued at approximately $9,582,009.17. The trade was a 1.80 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Michael A. Boxer sold 3,775 shares of the firm's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the transaction, the senior vice president now directly owns 10,816 shares of the company's stock, valued at $5,759,736.32. This represents a 25.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 23,900 shares of company stock worth $13,106,062 over the last ninety days. Company insiders own 0.34% of the company's stock.
Thermo Fisher Scientific Profile
(
Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Recommended Stories
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
